Evidence map›Paper›PMID 26223635›Full record

ArticleJournal of virology2015

An A14U Substitution in the 3' Noncoding Region of the M Segment of Viral RNA Supports Replication of Influenza Virus with an NS1 Deletion by Modulating Alternative Splicing of M Segment mRNAs.

Min Zheng, Pui Wang, Wenjun Song, Siu-Ying Lau, Siwen Liu, Xiaofeng Huang, Bobo Wing-Yee Mok, Yen-Chin Liu, Yixin Chen, Kwok-Yung Yuen and 1 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04809389 phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults

TypeinterventionalSponsorThe University of Hong KongRan2021 to 2022Enrolled115ConditionsCovid19ArmsDelNS1-nCoV-RBD LAIV, Matching placebo
NCT05200741 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as Booster Vaccine for COVID-19 in Healthy Adults Who Have Received 2 Doses of BNT162b2

TypeinterventionalSponsorThe University of Hong KongRan2022 to 2024Enrolled150ConditionsCovid19ArmsDelNS1-2019-nCoV-RBD-OPT1, Matching placebo
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Influenza NS1 drives NEmerging microbes & infections · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Min ZhengState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the University of Hong Kong, Hong Kong SAR, People's Republic of China.
Pui WangState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the University of Hong Kong, Hong Kong SAR, People's Republic of China.
Wenjun SongState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the University of Hong Kong, Hong Kong SAR, People's Republic of China.
Siu-Ying LauState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.
Siwen LiuState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.
Xiaofeng HuangState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.
Bobo Wing-Yee MokState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.
Yen-Chin LiuState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China.
Yixin ChenNational Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, People's Republic of China.
Kwok-Yung YuenState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the University of Hong Kong, Hong Kong SAR, People's Republic of China kyyuen@hku.hk hlchen@hku.hk.
Honglin ChenState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, and Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong SAR, People's Republic of China Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the University of Hong Kong, Hong Kong SAR, People's Republic of China kyyuen@hku.hk hlchen@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe NS1 protein of influenza virus has multiple functions and is a determinant of virulence. Influenza viruses with NS1 deletions (DelNS1 influenza viruses) are a useful tool for studying virus replication and can serve as effective live attenuated vaccines, but deletion of NS1 severely diminishes virus replication, hampering functional studies and vaccine production. We found that WSN-DelNS1 viruses passaged in cells consistently adapted to gain an A14U substitution in the 3' noncoding region of the M segment of viral RNA (vRNA) which restored replicative ability. DelNS1-M-A14U viruses cannot inhibit interferon expression in virus infected-cells, providing an essential model for studying virus replication in the absence of the NS1 protein. Characterization of DelNS1-M-A14U virus showed that the lack of NS1 has no apparent effect on expression of other viral proteins, with the exception of M mRNAs. Expression of the M transcripts, M1, M2, mRNA3, and mRNA4, is regulated by alternative splicing. The A14U substitution changes the splicing donor site consensus sequence of mRNA3, altering expression of M transcripts, with M2 expression significantly increased and mRNA3 markedly suppressed in DelNS1-M-A14U, but not DelNS1-M-WT, virus-infected cells. Further analysis revealed that the A14U substitution also affects promoter function during replication of the viral genome. The M-A14U mutation increases M vRNA synthesis in DelNS1 virus infection and enhances alternative splicing of M2 mRNA in the absence of other viral proteins. The findings demonstrate that NS1 is directly involved in influenza virus replication through modulation of alternative splicing of M transcripts and provide strategic information important to construction of vaccine strains with NS1 deletions. IMPORTANCE: Nonstructural protein (NS1) of influenza virus has multiple functions. Besides its role in antagonizing host antiviral activity, NS1 is also believed to be involved in regulating virus replication, but mechanistic details are not clear. The NS1 protein is a virulence determinant which inhibits both innate and adaptive immunity and live attenuated viruses with NS1 deletions show promise as effective vaccines. However, deletion of NS1 causes severe attenuation of virus replication during infection, impeding functional studies and vaccine development. We characterized a replication-competent DelNS1 virus which carries an A14U substitution in the 3' noncoding region of the vRNA M segment. We found that M-A14U mutation supports virus replication through modulation of alternative splicing of mRNAs transcribed from the M segment. Our findings give insight into the role of NS1 in influenza virus replication and provide an approach for constructing replication-competent strains with NS1 deletions for use in functional and vaccine studies.

Indexed as

Alternative SplicingGenome, Viral3' Untranslated RegionsAnimalsBase SequenceChlorocebus aethiopsDogsHEK293 CellsHumansInfluenza A virusMadin Darby Canine Kidney CellsMolecular Sequence DataPoint MutationRNA Splice SitesRNA, ViralSequence Deletion3' Untranslated RegionsINS1 protein, influenza virusRNA Splice SitesRNA, ViralViral Nonstructural Proteins

Identifiers

PMID26223635
PMCPMC4580205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.